About 17 out of every 100 men in the United States will be diagnosed with prostate cancer in their lifetime. However, fewer than 3 out of every 100 men in the United States will die from prostate cancer.

Men with clinically localized prostate cancer have many options for managing their cancer, including the option to abstain from immediate treatment. There is also time to think about the options, since prostate cancer often progresses slowly. Men may be better able to understand and consider their options if they are presented with the benefits and harms of each option within an interactive Web-based tool. Patient decision aids, such as this one, are designed to support decisionmaking and patient involvement when making complex decisions.

Educational Content

This decision aid was designed to better prepare men with clinically localized prostate cancer to participate in decisionmaking with their doctor regarding their treatment options. The program covers the following information:

- The location and function of the prostate gland.
- What it means to have localized prostate cancer.
- Treatment options after being diagnosed with localized prostate cancer, including the option to choose not to begin treatment immediately.
- Treatment options that may be available based on available testing.

Target Audience

This patient decision aid is designed to meet the educational needs of English-speaking men, diagnosed with localized prostate cancer, who are considering available treatment options.
Method of Participation
The program content is presented as a series of modules using a variety of visual formats including animation, graphics, picture stills, and text. A printout may be obtained at the end of the Web-based tool containing elements that may be used by patients to discuss treatment options with their doctor and/or significant others.

Application of IPDAS Standards for Development of the Patient Decision Aid
The original version of the International Patient Decision Aid Standards (IPDAS) checklist was developed following the two-stage Delphi consensus process involving decision aid developers, researchers, practitioners, patients, and policymakers.

Different versions of the IPDAS standards have been developed since the original checklist was offered. The approach, used by the Ottawa Health Research Institute, was adopted by the John M. Eisenberg Center for Clinical Decisions and Communications Science at Baylor College of Medicine (EC-BCM) as quality standards for patient decision aids. Briefly, the Ottawa Health Research Institute identified an abbreviated set of criteria from the checklist, retaining only those criteria where the median importance rating was 9 on a 1 – 9 point scale (31 criteria total). In other words, only those criteria where complete agreement of the voting panel was achieved have been retained. This abbreviated version is listed below, organized by the following categories: content items (Table 1), development process items (Table 2), and effectiveness items (Table 3). The tables presented in the following pages include a checklist of these standards indicating whether components of the patient decision aid, “Knowing Your Options: A Decision Aid for Men With Localized Prostate Cancer,” includes the criteria identified. In some instances, the standards are not applicable as indicated.

Table 1a. Abbreviated IPDAS Checklist: Content Items

<table>
<thead>
<tr>
<th>IPDAS CHECKLIST CRITERIA</th>
<th>YES</th>
<th>NO</th>
<th>N/A</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CONTENT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>01 Does the patient decision aid provide information about the options in sufficient detail for decisionmaking?</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02 The decision aid describes the condition (health or other) related to the decision.</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>03 The decision aid describes the decision that needs to be considered (the index decision).</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>04 The decision aid lists the options (health care or other).</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>05 The decision aid describes what happens in the natural course of the condition (health or other) if no action is taken.</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>06 The decision aid has information about the procedures involved (e.g., what is done before, during, and after the health care option).</td>
<td>●</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 1b. Abbreviated IPDAS Checklist: Content Items (continued)

<table>
<thead>
<tr>
<th>IPDAS CHECKLIST CRITERIA</th>
<th>YES</th>
<th>NO</th>
<th>N/A</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CONTENT (continued)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07 The decision aid has information about the positive features of the options (e.g., benefits, advantages).</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08 The decision aid has information about negative features of the options (e.g., harms, side effects, disadvantages).</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09 The information about outcomes of options (positive and negative) includes the chances they may happen.</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 The decision aid has information about what the test is designed to measure.</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>This is a treatment aid.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 The decision aid describes possible next steps based on the test results.</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>This is a treatment aid.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 The decision aid has information about the chances of disease being found with and without screening.</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>This is a treatment aid.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 The decision aid has information about detection and treatment of disease that would never have caused problems if screening had not been done.</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14 The decision aid presents probabilities using event rates in a defined group of people for a specified time.</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Data on outcome probabilities are lacking, and groups are not directly comparable.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15 The decision aid compares probabilities (e.g., chance of a disease, benefit, harm, or side effect) of options using the same denominator.</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Data on outcome probabilities directly comparing options are lacking.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 The decision aid compares probabilities of options over the same period of time.</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Data on outcome probabilities directly comparing options are lacking.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17 The decision aid uses the same scales in diagrams comparing options.</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Data on outcome probabilities directly comparing options are lacking.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18 The decision aid asks people to think about which positive and negative features of the options matter most to them.</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19 The decision aid makes it possible to compare the positive and negative features of the available options.</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 The decision aid shows the negative and positive features of the options with equal detail.</td>
<td></td>
<td>●</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 2. Abbreviated IPDAS Checklist: Development Process Items

<table>
<thead>
<tr>
<th>IPDAS CHECKLIST CRITERIA</th>
<th>YES</th>
<th>NO</th>
<th>N/A</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEVELOPMENT PROCESS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21 Users (people who previously faced the decision) were asked what they need to prepare</td>
<td></td>
<td></td>
<td></td>
<td>Field testing was conducted with prostate cancer patients.</td>
</tr>
<tr>
<td>them to discuss a specific decision.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22 The decision aid was reviewed by people who previously faced the decision who were</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>not involved in its development and field testing.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23 People who were facing the decision field tested the decision aid.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 Field testing showed that the decision aid was acceptable to users (the general public</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>and practitioners).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25 Field testing showed that people who were undecided felt that the information was</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>presented in a balanced way.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26 The decision aid provides references to scientific evidence used.</td>
<td></td>
<td></td>
<td></td>
<td>References are included in this document.</td>
</tr>
<tr>
<td>27 The decision aid reports the date when it was last updated.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28 The decision aid reports whether authors of the decision aid or their affiliations stand</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>to gain or lose by choices people make after using the decision aid.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29 The decision aid is understood by those with limited reading skills.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 3. Abbreviated IPDAS Checklist: Effectiveness Items

<table>
<thead>
<tr>
<th>IPDAS CHECKLIST CRITERIA</th>
<th>YES</th>
<th>NO</th>
<th>N/A</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>EFFECTIVENESS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30 There is evidence that the decision aid (or one based on the same template) helps</td>
<td></td>
<td></td>
<td></td>
<td>The aid’s effectiveness has not yet been evaluated.</td>
</tr>
<tr>
<td>people know about the available options and their features.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31 There is evidence that the decision aid (or one based on the same template) improves</td>
<td></td>
<td></td>
<td></td>
<td>The aid’s effectiveness has not yet been evaluated.</td>
</tr>
<tr>
<td>the match between the features that matter most to the informed person and the</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>option that is chosen.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Disclaimer

The content provided in the patient decision aid does not replace the advice of a doctor. The Agency for Healthcare Research and Quality (AHRQ) makes every effort to have accurate information presented. The information provided in this program is intended for educational purposes only.

AHRQ is not responsible for how the information is used; that is, no warranty or liability is offered. Links are provided to other Internet sites only for the ease of users and does not constitute an endorsement. Once the user links to another site, he/she is subject to that site's terms and conditions.

All medical decisions should be made in consultation with a doctor.

Acknowledgement of Support

This patient decision aid is supported by a contract, HHSA290200810015C, from the Agency for Healthcare Research and Quality.

Production Release Date and Updating Policy

The release of this patient decision aid is scheduled for September 8, 2011.

Updating of this aid will coincide with updates to the Comparative Effectiveness Review that serves as the primary evidence source and other supporting evidence provided by AHRQ's Effective Health Care Program. The timing of updates will be determined by AHRQ.
BCM Development Team – Disclosure (Current Aid, 2011)

The content and design of the current patient decision aid entitled, Knowing Your Options: A Decision Aid for Men With Localized Prostate Cancer, was developed by a team of experts at AHRQ’s John M. Eisenberg Center for Clinical Decisions and Communications Science at Baylor College of Medicine (BCM) (Houston, Texas) in collaboration with a subcontracted team of experts at the University of Texas MD Anderson Cancer Center (Houston, Texas). This work was informed by the previous efforts of faculty and staff at the Oregon Health and Science University (OHSU) (Portland, Oregon) who had developed an unpublished decision aid on prostate cancer.

AHRQ must assure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities and programs. Thus, all individuals who participate in sponsored activities, including members of expert content committees, are expected to disclose any significant relationships that may pose a conflict with the principles of balance and independence.

Disclosure: Nothing to disclose.

Leads

Robert J. Volk, PhD
Professor, Department of General Internal Medicine, Division of Internal Medicine
The University of Texas MD Anderson Cancer Center, Houston, Texas
Director, Communication and Decision Support Research Core
John M. Eisenberg Center for Clinical Decisions and Communications Science
Baylor College of Medicine, Houston, Texas

Michael Fordis, MD
Director, Center for Collaborative and Interactive Technologies
Director, John M. Eisenberg Center for Clinical Decisions and Communications Science
Senior Associate Dean for Continuing Medical Education
Baylor College of Medicine, Houston, Texas

Project Management Team

Ying Yeung, MHA
Associate Director, Center for Collaborative and Interactive Technologies
Associate Director, John M. Eisenberg Center for Clinical Decisions and Communications Science
Assistant Professor, School of Allied Health Sciences
Baylor College of Medicine, Houston, Texas

Daniel Doyle, MS
Lead Project Manager, John M. Eisenberg Center for Clinical Decisions and Communications Science
Baylor College of Medicine, Houston, Texas

Bonnie Nelson, MEd
Project Manager, Development and Testing
Department of General Internal Medicine, Division of Internal Medicine
The University of Texas MD Anderson Cancer Center, Houston, Texas
ABOUT THE DECISION AID

Knowing Your Options: A Decision Aid for Men With Localized Prostate Cancer

Writing/Editing Team

Emily White, MS
Medical Writer
John M. Eisenberg Center for Clinical Decisions and Communications Science
Baylor College of Medicine, Houston, Texas

Thomas Workman, PhD
Production Section Head
Assistant Professor, School of Allied Health Sciences
John M. Eisenberg Center for Clinical Decisions and Communications Science
Baylor College of Medicine, Houston, Texas

Pamela Paradis Metoyer, ELS(D)
Medical Editor
Center for Collaborative and Interactive Technologies
John M. Eisenberg Center for Clinical Decisions and Communications Science
Baylor College of Medicine, Houston, Texas

Decision Design Team

Scott Cantor, PhD
Associate Professor, Department of Biostatistics
The University of Texas MD Anderson Cancer Center, Houston, Texas

Michael Kallen, PhD, MPH
Assistant Professor, Department of General Internal Medicine, Division of Internal Medicine
The University of Texas MD Anderson Cancer Center, Houston, Texas

Maria Jibaja-Weiss, DrPH
Associate Professor, School of Allied Health Sciences
Baylor College of Medicine, Houston, Texas

Zubin Segal, MPH
Senior Research Coordinator
Department of General Internal Medicine, Division of Internal Medicine
The University of Texas MD Anderson Cancer Center, Houston, Texas

Richard L. Street, PhD
Professor and Head, Department of Communication
Texas A&M University, College Station, Texas
Assistant Professor of Medicine
Baylor College of Medicine, Houston, Texas

Ali Zalpour, PharmD, BCPS
Clinical Pharmacy Specialist
Department of General Internal Medicine, Division of Internal Medicine
The University of Texas MD Anderson Cancer Center, Houston, Texas
Web Development and Design Team

Doug Alexander  
Lead Designer and Information Architect  
Center for Collaborative and Interactive Technologies  
John M. Eisenberg Center for Clinical Decisions and Communications Science  
Baylor College of Medicine, Houston, Texas

Andy Nystrom  
Designer  
John M. Eisenberg Center for Clinical Decisions and Communications Science  
Baylor College of Medicine, Houston, Texas

Medical Content Experts

Deborah A. Kuban, MD  
Professor, Radiation Oncology Department  
The University of Texas MD Anderson Cancer Center, Houston, Texas

Curtis A. Pettaway, MD  
Professor, Department of Urology  
The University of Texas MD Anderson Cancer Center, Houston, Texas
OHSU Development Team – Disclosure (Original Aid, 2008)

The content and design of the unpublished patient decision aid entitled, *Making Decisions About Prostate Cancer*, was developed by a team of experts at the Oregon Health and Science University (Portland, Oregon).

**Disclosure:** Nothing to disclose.

**OHSU Team**

**David Hickam, MD, MPH**  
Professor, Department of Medicine  
Oregon Health and Science University, Portland, Oregon

**Karen Eden, PhD**  
Associate Professor, Department of Medical Informatics and Clinical Epidemiology  
Oregon Health and Science University, Portland, Oregon

**Anais Tuepker, PhD**  
Research Assistant Professor, Department of Medicine  
Oregon Health and Science University, Portland, Oregon

**Tom McTighe**  
Web Specialist  
Oregon Health and Science University, Portland, Oregon
References and Evidence Sources

Information about the epidemiology of prostate cancer and some details about treatment options were gathered from the National Cancer Institute Web site:

